Companies › Aston Sci.
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AST-301 (pNGVL3-hICD) Therapeutic cancer vaccine expressing human ICD (immunogenic cell death) | ERBB2 | Phase 2 | Gastric Cancer | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05771584 | AST-301 (pNGVL3-hICD) | Phase 2 | Gastric Cancer | Oncology | Feb 2027 |
Chengdu SciMount Pharmatech Shanghai Miracogen SystImmune DualityBio Partner Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.